QTC Medical Services

QTC Medical Services, Inc. (QTC), a subsidiary of Leidos (NYSE: LDOS), has officially inaugurated its latest cutting-edge clinic facility in Fairfax, Virginia. This facility is designed to offer a comprehensive range of healthcare services catering to U.S. military veterans, transitioning and retiring service members, active duty and reserve service members, as well as civilians. Notably, the clinic’s scope of services extends to include the Federal Occupational Health program of the U.S. Department of Health and Human Services, along with various U.S. government intelligence programs.

Liz Porter, President of Leidos Health Group, expressed pride in the opening of this state-of-the-art facility and emphasized its role in unleashing innovative solutions for the military and federal communities. She affirmed Leidos’ ongoing commitment to providing exceptional and streamlined care through advanced health delivery solutions with the establishment of this flagship QTC clinic.

What is QTC business?

Larry Schaefer, the Chief Executive Officer of QTC, reaffirmed the company’s unwavering commitment to both local and national government agencies, stating, “QTC remains steadfast in its commitment to local and national government agencies. We’re honored and excited to support examinees through this new flagship clinic.

U.S. Senator Tim Kaine emphasized the importance of timely healthcare for servicemembers and veterans, declaring, “No servicemember or veteran should face long wait times to receive the health care they need. I’m excited to see how QTC Medical Services’ innovative approach and this new state-of-the-art facility will help provide high-quality, timely health care to Virginia’s servicemembers and veterans in Northern Virginia.

U.S. Representative Gerry Connolly expressed his enthusiasm for the addition of the new clinic to Fairfax, stating, “I am thrilled to welcome this new clinic to Fairfax. Northern Virginia is a hub for state-of-the-art medical care, and this clinic will only bolster those credentials. I look forward to the excellent care they will provide for many years to come.

Who is QTc medical services?

QTC Management, Inc. (QTC), a subsidiary of Leidos, collaborates closely with its clients to identify both current and future program needs, providing a comprehensive range of medical examination and diagnostic testing services with a focus on disabilities. Since its establishment in 2000, QTC has successfully conducted over 12 million physical examinations and diagnostic tests. For additional details, please visit www.qtcm.com.

It’s important to note that certain statements in this announcement are considered “forward-looking statements” in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC). These statements reflect the current beliefs and expectations of management but are inherently subject to significant risks and uncertainties. They should not be regarded as guarantees of future results or events. Various factors could lead to actual results, performance, achievements, or industry outcomes differing from those expressed or implied by these forward-looking statements.

These factors encompass, but are not limited to, the “Risk Factors” outlined in Leidos’ Annual Report on Form 10-K for the fiscal year concluded on December 30, 2022, and other similar filings made by Leidos with the SEC periodically. Readers are advised to exercise caution and not unduly rely on these forward-looking statements, as they speak only as of the date of this announcement. Leidos undertakes no obligation to update such forward-looking statements to reflect the impact of circumstances or events that may arise after the date of the initial forward-looking statements.

What is QTC examination?

C&P examinations play a pivotal role as crucial pieces of evidence in assessing the extent of permanent impairment, thereby determining the percentage of disability that defines the benefits awarded to veterans. Compensation, a monetary benefit, is provided to veterans who have been disabled due to injury or disease incurred or aggravated during active military service. For eligibility, the veteran’s service must have concluded through separation or discharge under conditions other than dishonorable.

Pension benefits, on the other hand, are accessible to veterans with limited income and a minimum of 90 days of active military service, including at least one day during a wartime period. To qualify, the veteran’s discharge from active duty must be under conditions other than dishonorable. Additionally, they must be permanently and totally disabled, with the disability not attributable to military service or willful misconduct. These distinctions in benefits underscore the commitment to supporting veterans based on the circumstances surrounding their service and the resulting impact on their well-being.

While citalopram is a racemate of S-citalopram (active) and R-citalopram (inactive), it is noteworthy that the updated FDA advisory solely focused on citalopram. The advisory explicitly stated that ‘there are no changes planned for escitalopram at this time.’ A notable group [30R] addressed whether similar concerns should apply to escitalopram, whose maximum FDA labeling remains at 20 mg per day. These authors observed that doses of escitalopram exceeding 20 mg could reasonably be expected to cause some degree of QTc prolongation, comparable to doses exceeding 40 mg of the racemate.

What does QTC do?

In August 2011, the FDA prohibited the use of citalopram at doses exceeding 40 mg per day, or 20 mg daily for individuals aged 60 and above. This regulatory action was prompted by postmarketing reports indicating a correlation between citalopram and the prolonged QTc interval syndrome, as well as torsade de pointes. An unpublished study evaluating the impact of both 20 mg and 60 mg daily doses of citalopram on the QTc interval in adults further supported this advisory warning.

Subsequent to the initial announcement, the FDA delved deeper into the cardiac effects of citalopram in March 2012 [28S]. The matter continued to be thoroughly investigated by independent researchers. A cross-sectional study, incorporating ECG data, prescription records, and clinical information from electronic health records, confirmed the effect of citalopram on the QTc interval [29C]. This comprehensive analysis, involving 38,397 patients who underwent ECG following antidepressant prescription, revealed a significant dose–response relationship for QTc prolongation associated with citalopram, as well as escitalopram and amitriptyline. These findings underscore the ongoing scrutiny and awareness surrounding the cardiac implications of citalopram usage.

FDA data indicated that 60 mg of citalopram prolonged QTc by 18.5 ms, compared to an equivalent 30 mg of escitalopram, which prolonged QTc by 10.7 ms. This suggested that the effect was not solely due to R-citalopram, and the therapeutically active S-isomer also played a role. The Sheeler group concluded that, as escitalopram demonstrated potential for QTc prolongation, merely transitioning from citalopram to escitalopram would not entirely eliminate the risk. Others suggested that, as the R-isomer of citalopram offered no additional antidepressant benefit while potentially contributing to harmful effects on QTc prolongation, it would be prudent to transition all patients to the equivalent dose of escitalopram.

Is QTC a real company?

The March 2012 advisory from the FDA discouraged the use of citalopram in individuals at risk of QT prolongation, such as those with pre-existing heart conditions or a predisposition to hypokalemia or hypomagnesemia. However, the advisory adjusted the label to ‘recommend caution’ instead of maintaining a strict contraindication. It acknowledged that if citalopram were to be used due to a lack of suitable alternatives, patients should undergo electrolyte and ECG monitoring. The FDA maintained its advice for a maximum dose of 20 mg for genetic CYP2C19 poor metabolizers or those taking medications that may inhibit CYP2C19, including proton pump inhibitors (e.g., omeprazole), cimetidine, macrolide antibiotics, and oral contraceptives.

For patients with congenital long QT syndrome, the labeling recommendation shifted from ‘contraindicated’ to ‘not recommended,’ recognizing that some individuals with this syndrome might lack viable alternatives. Additionally, the advisory recommended discontinuing citalopram in cases where patients exhibited a persistent QTc interval greater than 500 ms, building upon the earlier label warning.